• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Health care M&A activity hits record level

By
Dan Primack
Dan Primack
Down Arrow Button Icon
By
Dan Primack
Dan Primack
Down Arrow Button Icon
April 24, 2014, 4:39 PM ET

FORTUNE — The year-to-date level of announced M&A activity in the health care sector is at its highest level since Thomson Reuters (TRI) began tracking such deals in 1980, hitting $153.5 billion. Approximately 71% of that volume is in the pharmaceutical sector, followed by health care equipment and technology.

Source: Thomson Reuters

If this isn’t something you really saw coming, that’s probably because around $88.1 billion of that $153.5 billion came just this week. Namely from four transactions:

  • Zimmer Holdings Inc. (ZMH) today agreed to acquire Biomet Inc., a Warsaw, Ind.-based maker of medical devices like dental implants and artificial hips joints. The deal is valued at approximately $13.35 billion, including the assumption of net debt. Biomet was taken private for $11.4 billion in 2007 by The Blackstone Group, GS Capital Partners, KKR and TPG Capital. It had been expected to file for an IPO. www.biomet.com
  • Novartis (NVS) agreed to acquire the oncology drug business of GlaxoSmithKline (GSK) for upwards of $16 billion, while selling its vaccine business to GSK for $7.1 billion. The two companies also will combine their consumer drug businesses.
  • Novartis also agreed to sell its animal health business to Eli Lilly (LLY) for $5.4 billion.
  • Valeant Pharmaceuticals International Inc. (VRX) offered to acquire Botox maker Allergan Inc. (AGN) for approximately $50 billion in cash and stock. The offer is worth approximately $152.88 per Allergan share (including $48.30 in cash), which represents a 31% premium to Allegan’s price before Bill Ackman’s Pershing Square Capital Management revealed on April 10 that it had acquired more than a 5% interest in the company. Pershing Square now holds around a 9.7% stake in Allergan, and is partnering with Valeant on the takeover bid. It is worth noting that Allergan has not yet accepted or rejected the offer.

Goldman Sachs (GS) is the year’s top advisor so far on health care M&A, having worked on the Allergan, Novartis Animal Health and Biomet transactions.

Sign up for Dan Primack’s daily email newsletter on deals and deal-makers: GetTermSheet.com

About the Author
By Dan Primack
See full bioRight Arrow Button Icon

Latest in

EconomyFederal Reserve
The Fed just ‘Trump-proofed’ itself with a unanimous move to preempt a potential leadership shakeup
By Jason MaDecember 12, 2025
1 hour ago
Healthmeal delivery
Factor Meals Review 2025: Tester Approved
By Christina SnyderDecember 12, 2025
2 hours ago
robots
InnovationRobots
‘The question is really just how long it will take’: Over 2,000 gather at Humanoids Summit to meet the robots who may take their jobs someday
By Matt O'Brien and The Associated PressDecember 12, 2025
2 hours ago
Trump
PoliticsWhite House
House Democrats release new Epstein photos including Trump, Clinton, Prince Andrew
By Stephen Groves and The Associated PressDecember 12, 2025
2 hours ago
Sherrone Moore
LawMichigan
Michigan mystery revealed: Fired football coach had broken into a lover’s apartment and threatened to kill himself when their affair ended
By Ed White and The Associated PressDecember 12, 2025
2 hours ago
Orlando
LawTheme parks
32-year-old’s death on Universal roller coaster was accidental despite deep forehead gash, investigation finds
By Mike Schneider and The Associated PressDecember 12, 2025
2 hours ago

Most Popular

placeholder alt text
Economy
Tariffs are taxes and they were used to finance the federal government until the 1913 income tax. A top economist breaks it down
By Kent JonesDecember 12, 2025
12 hours ago
placeholder alt text
Success
At 18, doctors gave him three hours to live. He played video games from his hospital bed—and now, he’s built a $10 million-a-year video game studio
By Preston ForeDecember 10, 2025
3 days ago
placeholder alt text
Success
Palantir cofounder calls elite college undergrads a ‘loser generation’ as data reveals rise in students seeking support for disabilities, like ADHD
By Preston ForeDecember 11, 2025
1 day ago
placeholder alt text
Arts & Entertainment
'We're not just going to want to be fed AI slop for 16 hours a day': Analyst sees Disney/OpenAI deal as a dividing line in entertainment history
By Nick LichtenbergDecember 11, 2025
1 day ago
placeholder alt text
Uncategorized
Transforming customer support through intelligent AI operations
By Lauren ChomiukNovember 26, 2025
16 days ago
placeholder alt text
Economy
‘We have not seen this rosy picture’: ADP’s chief economist warns the real economy is pretty different from Wall Street’s bullish outlook
By Eleanor PringleDecember 11, 2025
1 day ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.